Please assess the completion status of the following clinical trial:

Trial Title: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female aged 18 to 75 years, inclusive.~* Patient has moderately to severely active UC with a modified Mayo score of 5 to 9 points with endoscopic subscore of ≥ 2 points~Exclusion Criteria:~* Patient who has previously received 2 or more biologic agents and/or JAK inhibitors~* Patient who has previously received either a TNFα inhibitor or biologic agent within 5 half-lives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CT-P13 SC (Type: EXPERIMENTAL): None
- Placebo SC (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).